Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:18690434rdf:typepubmed:Citationlld:pubmed
pubmed-article:18690434lifeskim:mentionsumls-concept:C0027651lld:lifeskim
pubmed-article:18690434lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:18690434lifeskim:mentionsumls-concept:C0011923lld:lifeskim
pubmed-article:18690434lifeskim:mentionsumls-concept:C0027930lld:lifeskim
pubmed-article:18690434lifeskim:mentionsumls-concept:C0182638lld:lifeskim
pubmed-article:18690434lifeskim:mentionsumls-concept:C0205360lld:lifeskim
pubmed-article:18690434lifeskim:mentionsumls-concept:C0599894lld:lifeskim
pubmed-article:18690434lifeskim:mentionsumls-concept:C1521840lld:lifeskim
pubmed-article:18690434pubmed:issue1lld:pubmed
pubmed-article:18690434pubmed:dateCreated2008-12-5lld:pubmed
pubmed-article:18690434pubmed:abstractTextNeurotensin (NT) and its high affinity receptor (NTR1) are involved in several neoplastic processes. Thus, NT-based radiopharmaceuticals are potential tracers for targeted diagnosis and therapy of NTR-positive tumours. A new analogue based on NT(8-13), NT-XIX, with the three enzymatic cleavage sites stabilised, was synthesised and tested.lld:pubmed
pubmed-article:18690434pubmed:languageenglld:pubmed
pubmed-article:18690434pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18690434pubmed:citationSubsetIMlld:pubmed
pubmed-article:18690434pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18690434pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18690434pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18690434pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18690434pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18690434pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18690434pubmed:statusMEDLINElld:pubmed
pubmed-article:18690434pubmed:monthJanlld:pubmed
pubmed-article:18690434pubmed:issn1619-7089lld:pubmed
pubmed-article:18690434pubmed:authorpubmed-author:SchubigerP...lld:pubmed
pubmed-article:18690434pubmed:authorpubmed-author:TourwéDirkDlld:pubmed
pubmed-article:18690434pubmed:authorpubmed-author:García-Garayo...lld:pubmed
pubmed-article:18690434pubmed:authorpubmed-author:BläuensteinPe...lld:pubmed
pubmed-article:18690434pubmed:authorpubmed-author:BlancAlainAlld:pubmed
pubmed-article:18690434pubmed:authorpubmed-author:MaesVeronique...lld:pubmed
pubmed-article:18690434pubmed:issnTypeElectroniclld:pubmed
pubmed-article:18690434pubmed:volume36lld:pubmed
pubmed-article:18690434pubmed:ownerNLMlld:pubmed
pubmed-article:18690434pubmed:authorsCompleteYlld:pubmed
pubmed-article:18690434pubmed:pagination37-47lld:pubmed
pubmed-article:18690434pubmed:meshHeadingpubmed-meshheading:18690434...lld:pubmed
pubmed-article:18690434pubmed:meshHeadingpubmed-meshheading:18690434...lld:pubmed
pubmed-article:18690434pubmed:meshHeadingpubmed-meshheading:18690434...lld:pubmed
pubmed-article:18690434pubmed:meshHeadingpubmed-meshheading:18690434...lld:pubmed
pubmed-article:18690434pubmed:meshHeadingpubmed-meshheading:18690434...lld:pubmed
pubmed-article:18690434pubmed:meshHeadingpubmed-meshheading:18690434...lld:pubmed
pubmed-article:18690434pubmed:meshHeadingpubmed-meshheading:18690434...lld:pubmed
pubmed-article:18690434pubmed:meshHeadingpubmed-meshheading:18690434...lld:pubmed
pubmed-article:18690434pubmed:meshHeadingpubmed-meshheading:18690434...lld:pubmed
pubmed-article:18690434pubmed:meshHeadingpubmed-meshheading:18690434...lld:pubmed
pubmed-article:18690434pubmed:meshHeadingpubmed-meshheading:18690434...lld:pubmed
pubmed-article:18690434pubmed:meshHeadingpubmed-meshheading:18690434...lld:pubmed
pubmed-article:18690434pubmed:meshHeadingpubmed-meshheading:18690434...lld:pubmed
pubmed-article:18690434pubmed:meshHeadingpubmed-meshheading:18690434...lld:pubmed
pubmed-article:18690434pubmed:meshHeadingpubmed-meshheading:18690434...lld:pubmed
pubmed-article:18690434pubmed:meshHeadingpubmed-meshheading:18690434...lld:pubmed
pubmed-article:18690434pubmed:meshHeadingpubmed-meshheading:18690434...lld:pubmed
pubmed-article:18690434pubmed:meshHeadingpubmed-meshheading:18690434...lld:pubmed
pubmed-article:18690434pubmed:meshHeadingpubmed-meshheading:18690434...lld:pubmed
pubmed-article:18690434pubmed:year2009lld:pubmed
pubmed-article:18690434pubmed:articleTitleA stable neurotensin-based radiopharmaceutical for targeted imaging and therapy of neurotensin receptor-positive tumours.lld:pubmed
pubmed-article:18690434pubmed:affiliationPaul Scherrer Institute, Center for Radiopharmaceutical Science, CH-5232, Villigen PSI, Switzerland. elisa.garcia@psi.chlld:pubmed
pubmed-article:18690434pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:18690434pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18690434lld:pubmed